The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ABBVIE INC | COM | 00287Y109 | 94 | 1,000 | SH | SOLE | 1,000 | 0 | 0 | ||
ACHILLION PHARMACEUTICALS INC | COM | 00448Q201 | 1,855 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
ALLERGAN PLC | SHS | G0177J108 | 57,891 | 344,000 | SH | SOLE | 344,000 | 0 | 0 | ||
APRICUS BIOSCIENCES INC | COM NEW | 03832V307 | 587 | 1,447,906 | SH | SOLE | 1,447,906 | 0 | 0 | ||
BIOGEN INC | COM | 09062X103 | 113,322 | 413,858 | SH | SOLE | 413,858 | 0 | 0 | ||
INNOVIVA INC | COM | 45781M101 | 61,023 | 3,660,705 | SH | SOLE | 3,660,705 | 0 | 0 | ||
INTERCEPT PHARMACEUTICALS INC | COM | 45845P108 | 39,083 | 635,300 | SH | SOLE | 635,300 | 0 | 0 | ||
IRONWOOD PHARMACEUTICALS INC | COM CL A | 46333X108 | 51,954 | 3,367,100 | SH | SOLE | 3,367,100 | 0 | 0 | ||
MEDICINES CO | COM | 584688105 | 63,310 | 1,922,000 | SH | SOLE | 1,922,000 | 0 | 0 | ||
NOVELION THERAPEUTICS INC | COM NEW | 67001K202 | 3,587 | 1,025,000 | SH | SOLE | 1,025,000 | 0 | 0 | ||
SHIRE PLC | SPONSORED ADR | 82481R106 | 39,438 | 264,000 | SH | SOLE | 264,000 | 0 | 0 |